Opinion
Volume 10:5, 2022

Journal of Clinical & Medical Genomics

ISSN: 2472-128X Open Access

Personalized Medicine from an Epidemiological Point of View: The Experience of Estonia

Sebastian Serin*

Department of Molecular Carcinogenesis, University of Cologne, Cologne, Germany

Introduction

Personalized medicine, also known as precision medicine, is a rapidly evolving field that seeks to tailor medical treatments to individual patients based on their genetic makeup, lifestyle, and other factors. In Estonia, personalized medicine has been a priority for over a decade, with the country investing heavily in the development of a national biobank and other infrastructure to support research in this area. In this essay, we will examine the Estonian experience of personalized medicine from an epidemiological perspective. One of the key drivers of personalized medicine in Estonia has been the Estonian Genome Project, which was launched in 2000 with the aim of creating a national biobank of genetic and health data. The project has been successful in collecting samples and data from a large proportion of the Estonian population, with over 200,000 participants to date. From an epidemiological perspective, the Estonian Genome Project has been a valuable resource for researchers studying the relationship between genetic factors and health outcomes. By collecting detailed genetic and health data on a large and diverse population, the project has enabled researchers to identify genetic risk factors for a range of diseases, including heart disease, diabetes, and certain types of cancer.

Description

In addition to the Estonian Genome Project, Estonia has also invested in other infrastructure to support personalized medicine research. For example, the country has developed a digital health system that allows patients to access their own health data and share it with healthcare providers and researchers. This system has been instrumental in facilitating research into personalized medicine, as it allows researchers to access large amounts of data on patient outcomes and treatments. Another key aspect of the Estonian approach to personalized medicine is its focus on collaboration and data sharing. The country has established a number of partnerships with international organizations, including the European Union's Horizon 2020 program and the US National Institutes of Health. These partnerships have enabled Estonian researchers to collaborate with leading experts in the field and to access additional resources and funding for their work. From an epidemiological perspective, this collaborative approach has been valuable in helping to build a global understanding of personalized medicine. By sharing data and expertise with international partners, Estonian researchers have been able to contribute to the development of new treatments and interventions that benefit patients around the world [1,2].

However, the Estonian experience of personalized medicine has not been without its challenges. One of the key challenges has been managing the large amounts of data generated by the Estonian Genome Project and other research initiatives. As personalized medicine relies on the collection and analysis of large amounts of personal health data, there is a risk that this information could be hacked, stolen, or used inappropriately. To address this risk, Estonia has implemented strict privacy and security protocols to protect patient data. Another challenge has been the need to balance the benefits of personalized medicine with the ethical and social implications of this approach. For example, there is a risk that personalized medicine could exacerbate existing healthcare disparities by making expensive treatments available only to those who can afford them [3-5].

Conclusion

To address this risk, Estonia has implemented policies to ensure that the benefits of personalized medicine are accessible to all patients, regardless of their income or background. Overall, the Estonian experience of personalized medicine provides valuable insights for epidemiologists and other researchers interested in this field. The country's investment in infrastructure, collaboration, and data sharing has enabled researchers to make significant advances in our understanding of the relationship between genetics and health outcomes. At the same time, the Estonian approach has also highlighted the importance of addressing the ethical and social implications of personalized medicine, and of implementing strict privacy and security protocols to protect patient data Looking forward, the Estonian experience suggests that personalized medicine will continue to be an important area of research and innovation in the years ahead. As technology advances and our understanding of genetics and disease continues to grow, personalized medicine has the potential to transform healthcare and improve patient outcomes

References

1. Flores, Valerie A and JoAnn E. Manson. "Patterns of menstrual cycle length over the menopause transition-a novel marker for cardiovascular risk?." *Menopause* 29 (2022): 1-2.
2. Kapoor, Ekta. "Menopause symptoms and the cortisol response." *Menopause* 29 (2022): 6-7.
3. Rathnayake, Nirmala, Janaka Lenora, Gayani Alwis and Sarath Lekamwasam. "Prevalence and severity of menopausal symptoms and the quality of life in middle-aged women: A study from Sri Lanka." *J Nurs Pract* 2019 (2019).
4. Olesen, Cathrine S., Trine Koch, Cecilie S. Uldbjerg and Laura S. Gregersen, et al. "Cardiovascular mortality after bilateral oophorectomy: A prospective cohort study." *Menopause* 29 (2022): 28-34.
5. Yixve, Mei Yixue, Jennifer S. Williams, Erin K. Webb and Alison K. Shea, et al. "Roles of hormone replacement therapy and menopause on osteoarthritis and cardiovascular disease outcomes: A narrative review." *Front rehabil sci* (2022): 45.

***Address for Correspondence:** Sebastian Serin, Department of Molecular Carcinogenesis, University of Cologne, Cologne, Germany, E-mail: Sebastianserin11@gmail.com*

Received: 01 September 2022, Manuscript No. jacm-23-96977; **Editor assigned:** 03 September 2022, PreQC No. P-96977; **Reviewed:** 15 September 2022, QC No. Q-96977; **Revised:** 22 September 2022, Manuscript No. R-96977; **Published:** 28 September 2022, DOI: 10.37421/2472-128X.2022.10.220

How to cite this article: Serin, Sebastian. "Personalized Medicine from an Epidemiological Point of View: The Experience of Estonia." *J Clin Med Genomics* 12 (2022): 220.